Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) insider Ariel Hurley sold 1,834 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $103.88, for a total value of $190,515.92. Following the completion of the sale, the insider now directly owns 14,913 shares of the company’s stock, valued at $1,549,162.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Blueprint Medicines Trading Down 0.9 %
Shares of NASDAQ:BPMC traded down $0.94 during midday trading on Monday, reaching $106.25. The company’s stock had a trading volume of 803,137 shares, compared to its average volume of 778,452. The firm has a market cap of $6.50 billion, a price-to-earnings ratio of -22.14 and a beta of 0.65. The company has a quick ratio of 3.61, a current ratio of 3.76 and a debt-to-equity ratio of 0.67. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $110.93. The business has a 50 day moving average price of $91.77 and a 200 day moving average price of $80.95.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The business had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. During the same quarter in the previous year, the business earned ($2.65) earnings per share. The business’s revenue for the quarter was up 85.5% on a year-over-year basis. Research analysts forecast that Blueprint Medicines Co. will post -5.38 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Research Report on BPMC
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BPMC. PNC Financial Services Group Inc. boosted its holdings in Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 329 shares during the last quarter. Cutler Group LLC CA lifted its stake in shares of Blueprint Medicines by 1,685.7% during the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 944 shares in the last quarter. Compass Wealth Management LLC acquired a new position in shares of Blueprint Medicines during the fourth quarter worth about $69,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Blueprint Medicines by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 757 shares in the last quarter. Finally, Van ECK Associates Corp lifted its stake in shares of Blueprint Medicines by 28.4% during the fourth quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 193 shares in the last quarter.
About Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Recommended Stories
- Five stocks we like better than Blueprint Medicines
- How to Find Undervalued Stocks
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Value Stocks You Can Buy Before They Become Big
- What is the Dow Jones Industrial Average (DJIA)?
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.